Singulex

company

About

Singulex develops direct molecular detection technology, cardiovascular monitoring, and related solutions to understand and manage diseases.

  • 101 - 250

Details

Last Funding Type
Series C
Last Funding Money Raised
$9.35M
Industries
Biotechnology,Health Care,Life Science,Medical
Founded date
Jan 1, 2003
Number Of Employee
101 - 250
Operating Status
Active

Singulex, Inc., a biotechnology company, develops and commercializes direct molecular detection technology solutions. Its solutions enable life science researchers and clinicians to understand and manage disease. The company develops biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers. It is conducting pilot studies to validate Erenna BioAssay System, a digital molecule detection platform, which detects and quantifies molecule biomarkers in clinical samples. The company also offers various custom assay services, such as pilot study services, assay prototyping, assay characterization, and assay validation. The company was formerly known as BioProfile Corporation and changed its name to Singulex, Inc in September 2003. Singulex is based in Hayward, California

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$28.35M
Singulex has raised a total of $28.35M in funding over 2 rounds. Their latest funding was raised on Jun 7, 2007 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 7, 2007 Series D $19M 1 Detail
Jul 17, 2006 Series C $9.35M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Singulex is funded by 1 investors. Advantage Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Advantage Capital Series D